We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · October 20, 2021

Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing

Clinical Cancer Research


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study
Clin. Cancer Res 2021 Oct 01;[EPub Ahead of Print], A Loehr, A Patnaik, D Campbell, J Shapiro, AH Bryce, R McDermott, B Sautois, NJ Vogelzang, RM Bambury, E Voog, J Zhang, JM Piulats, A Hussain, CJ Ryan, AS Merseburger, G Daugaard, A Heidenreich, K Fizazi, CS Higano, LE Krieger, C Sternberg, SP Watkins, D Despain, AD Simmons, M Dowson, T Golsorkhi, S Chowdhury, W Abida

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading